Amylyx Pharmaceuticals settles class action lawsuit for $6.5M over securities claims.

Amylyx Pharmaceuticals, Inc. and several defendants have agreed to a $6.5 million settlement in a class action lawsuit involving purchasers of Amylyx securities between November 2022 and November 2023. The settlement was approved by the U.S. District Court for the District of Massachusetts, with a hearing scheduled for September 10, 2026, to finalize the agreement. Eligible investors must submit claims by August 31, 2026, to receive compensation. This settlement resolves allegations of damages related to Amylyx securities during the specified period.